{
  "id": 8929012,
  "title": "Scotts Miracle-Gro stock hits 52-week low at 51.98 USD",
  "url": "https://urgent.news/2026/09/21/scotts-miracle-gro-stock-hits-52-week-low-at-51-98-usd",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-21T13:43:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/scotts-miraclegro-stock-hits-52week-low-at-5198-usd-93CH-4909234"
  },
  "original_language": "en",
  "account": null,
  "summary": "Scotts Miracle-Gro Company (SMG) stock has hit a 52-week low of $51.98, marking a 10.77% decrease over the past year. Despite this decline, the stock is considered undervalued by InvestingPro, appearing on their Most Undervalued list and boasting a 5.04% dividend yield. The stock is currently in oversold territory, according to the Relative Strength Index (RSI). Investors are closely monitoring the situation to assess future performance and potential recovery. Additionally, SMG has consistently paid dividends for 22 consecutive years. In more recent news, the company reported adjusted earnings of $2.82 per share for the fiscal third quarter of 2026, exceeding Wall Street's expectations. SMG raised its full-year adjusted EPS outlook following these results. UBS raised its price target for the company to $78 from $70, while Stifel increased its target to $76 from $75, both maintaining Neutral and Buy ratings, respectively. These developments highlight SMG's recent financial performance and future expectations.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Amneal Pharmaceuticals stock hits 52-week high at 19.32 USD",
        "url": "https://urgent.news/2026/09/21/amneal-pharmaceuticals-stock-hits-52-week-high-at-19-32-usd",
        "published": "2026-09-21T13:40:50.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}